163 related articles for article (PubMed ID: 19081719)
1. Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5).
Letourneau JJ; Liu J; Ohlmeyer MH; Riviello C; Rong Y; Li H; Appell KC; Bansal S; Jacob B; Wong A; Webb ML
Bioorg Med Chem Lett; 2009 Jan; 19(2):352-5. PubMed ID: 19081719
[TBL] [Abstract][Full Text] [Related]
2. Novel potent and selective alphavbeta3/alphavbeta5 integrin dual antagonists with reduced binding affinity for human serum albumin.
Raboisson P; Manthey CL; Chaikin M; Lattanze J; Crysler C; Leonard K; Pan W; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2006 Jul; 41(7):847-61. PubMed ID: 16697080
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel potent and selective alphavbeta3/alphavbeta5 integrin dual inhibitors with improved bioavailability. Selection of the molecular core.
Marugán JJ; Manthey C; Anaclerio B; Lafrance L; Lu T; Markotan T; Leonard KA; Crysler C; Eisennagel S; Dasgupta M; Tomczuk B
J Med Chem; 2005 Feb; 48(4):926-34. PubMed ID: 15715463
[TBL] [Abstract][Full Text] [Related]
5. Piperidine-containing beta-arylpropionic acids as potent antagonists of alphavbeta3/alphavbeta5 integrins.
De Corte BL; Kinney WA; Liu L; Ghosh S; Brunner L; Hoekstra WJ; Santulli RJ; Tuman RW; Baker J; Burns C; Proost JC; Tounge BA; Damiano BP; Maryanoff BE; Johnson DL; Galemmo RA
Bioorg Med Chem Lett; 2004 Oct; 14(20):5227-32. PubMed ID: 15380233
[TBL] [Abstract][Full Text] [Related]
6. Convergent, parallel synthesis of a series of beta-substituted 1,2,4-oxadiazole butanoic acids as potent and selective alpha(v)beta3 receptor antagonists.
Boys ML; Schretzman LA; Chandrakumar NS; Tollefson MB; Mohler SB; Downs VL; Penning TD; Russell MA; Wendt JA; Chen BB; Stenmark HG; Wu H; Spangler DP; Clare M; Desai BN; Khanna IK; Nguyen MN; Duffin T; Engleman VW; Finn MB; Freeman SK; Hanneke ML; Keene JL; Klover JA; Nickols GA; Nickols MA; Steininger CN; Westlin M; Westlin W; Yu YX; Wang Y; Dalton CR; Norring SA
Bioorg Med Chem Lett; 2006 Feb; 16(4):839-44. PubMed ID: 16298127
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of non-peptide alpha(v)beta(3)/alpha(5)beta(1) integrin dual antagonists containing 5,6-dihydropyridin-2-one scaffolds.
Benfatti F; Cardillo G; Fabbroni S; Galzerano P; Gentilucci L; Juris R; Tolomelli A; Baiula M; Spartà A; Spampinato S
Bioorg Med Chem; 2007 Dec; 15(23):7380-90. PubMed ID: 17869121
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part III: synthesis of potent antagonists with alpha(v)beta3/alpha(IIb)beta3 dual activity and improved water solubility.
Ishikawa M; Hiraiwa Y; Kubota D; Tsushima M; Watanabe T; Murakami S; Ouchi S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2131-50. PubMed ID: 16307881
[TBL] [Abstract][Full Text] [Related]
9. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 1: design and synthesis of a lead compound exhibiting alpha(v)beta3/alpha(IIb)beta3 dual antagonistic activity.
Kubota D; Ishikawa M; Yamamoto M; Murakami S; Hachisu M; Katano K; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2089-108. PubMed ID: 16309911
[TBL] [Abstract][Full Text] [Related]
10. Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Skuli N; Monferran S; Delmas C; Favre G; Bonnet J; Toulas C; Cohen-Jonathan Moyal E
Cancer Res; 2009 Apr; 69(8):3308-16. PubMed ID: 19351861
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of 2,5-thiazole butanoic acids as potent and selective alpha(v)beta3 integrin receptor antagonists with improved oral pharmacokinetic properties.
Wendt JA; Wu H; Stenmark HG; Boys ML; Downs VL; Penning TD; Chen BB; Wang Y; Duffin T; Finn MB; Keene JL; Engleman VW; Freeman SK; Hanneke ML; Shannon KE; Nickols MA; Steininger CN; Westlin M; Klover JA; Westlin W; Nickols GA; Russell MA
Bioorg Med Chem Lett; 2006 Feb; 16(4):845-9. PubMed ID: 16303301
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel potent and selective integrin alphanubeta3 antagonists--novel synthetic routes to isoquinolinone, benzoxazinone, and quinazolinone acetates.
Seitz W; Geneste H; Backfisch G; Delzer J; Graef C; Hornberger W; Kling A; Subkowski T; Zimmermann N
Bioorg Med Chem Lett; 2008 Jan; 18(2):527-31. PubMed ID: 18068982
[TBL] [Abstract][Full Text] [Related]
13. Tricyclic pharmacophore-based molecules as novel integrin alpha(v)beta3 antagonists. Part 2: synthesis of potent alpha(v)beta3/alpha(IIb)beta3 dual antagonists.
Ishikawa M; Kubota D; Yamamoto M; Kuroda C; Iguchi M; Koyanagi A; Murakami S; Ajito K
Bioorg Med Chem; 2006 Apr; 14(7):2109-30. PubMed ID: 16309912
[TBL] [Abstract][Full Text] [Related]
14. Suzuki-Miyaura approach to JNJ-26076713, an orally active tetrahydroquinoline-containing alphaVbeta3/alphaVbeta5 integrin antagonist. enantioselective synthesis and stereochemical studies.
Kinney WA; Teleha CA; Thompson AS; Newport M; Hansen R; Ballentine S; Ghosh S; Mahan A; Grasa G; Zanotti-Gerosa A; Dingenen J; Schubert C; Zhou Y; Leo GC; McComsey DF; Santulli RJ; Maryanoff BE
J Org Chem; 2008 Mar; 73(6):2302-10. PubMed ID: 18278942
[TBL] [Abstract][Full Text] [Related]
15. Role of alphav integrin in osteoprotegerin-induced endothelial cell migration and proliferation.
Kobayashi-Sakamoto M; Isogai E; Hirose K; Chiba I
Microvasc Res; 2008 Nov; 76(3):139-44. PubMed ID: 18656492
[TBL] [Abstract][Full Text] [Related]
16. Differential role of alpha(v)beta(3) and alpha(v)beta(5) integrins in internalization and transduction efficacies of wild type and RGD4C fiber-modified adenoviruses.
Majhen D; Nemet J; Richardson J; Gabrilovac J; Hajsig M; Osmak M; Eloit M; Ambriović-Ristov A
Virus Res; 2009 Jan; 139(1):64-73. PubMed ID: 19013487
[TBL] [Abstract][Full Text] [Related]
17. Discovery of diphenylmethanepropionic and dihydrostilbeneacetic acids as antagonists of the integrin alphavbeta3.
Nagarajan SR; Meyer JM; Miyashiro JM; Engleman VW; Freeman SK; Griggs DW; Klover JA; Nickols GA
Chem Biol Drug Des; 2006 Feb; 67(2):177-81. PubMed ID: 16492166
[TBL] [Abstract][Full Text] [Related]
18. Substituted benzocyloheptenes as potent and selective alpha(v) integrin antagonists.
Perron-Sierra F; Saint Dizier D; Bertrand M; Genton A; Tucker GC; Casara P
Bioorg Med Chem Lett; 2002 Nov; 12(22):3291-6. PubMed ID: 12392735
[TBL] [Abstract][Full Text] [Related]
19. Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.
Urbahns K; Härter M; Albers M; Schmidt D; Stelte-Ludwig B; Brüggemeier U; Vaupel A; Keldenich J; Lustig K; Tsujishita H; Gerdes C
Bioorg Med Chem Lett; 2007 Nov; 17(22):6151-4. PubMed ID: 17910915
[TBL] [Abstract][Full Text] [Related]
20. Discovery of +(2-{4-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]phenyl}-cyclopropyl)acetic acid as potent and selective alphavbeta3 inhibitor: design, synthesis, and optimization.
Nagarajan SR; Lu HF; Gasiecki AF; Khanna IK; Parikh MD; Desai BN; Rogers TE; Clare M; Chen BB; Russell MA; Keene JL; Duffin T; Engleman VW; Finn MB; Freeman SK; Klover JA; Nickols GA; Nickols MA; Shannon KE; Steininger CA; Westlin WF; Westlin MM; Williams ML
Bioorg Med Chem; 2007 May; 15(10):3390-412. PubMed ID: 17387018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
